Sentences with phrase «of pharmaceutical patent»

The Hatch - Waxman Act and the AIA balance exclusive rights of pharmaceutical patent holders with entry of generic competitors.

In a statement, The Council of Canadians points out the EU language was adopted on resolution of pharmaceutical patent disputes.

The suspended patent law provisions include those relating to patentable subject matter, and those providing patent term adjustments to compensate for unreasonable delays in patent issuance and unreasonable curtailment of the effective term of a pharmaceutical patent as a result of the marketing approval process.

On September 23, Canada's Competition Bureau («the Bureau») announced landmark guidelines regarding the consideration of pharmaceutical patent litigation settlements under Canada's competition law framework.

The PM (NOC) Regulations provide innovators of pharmaceutical patents («innovator») with an ability to list their patents on a Patent List.

Patent fights are nothing new in the pharmaceutical industry but a new report shows that during 2017 the number of legal battles of pharmaceutical patents increased by 30 percent.

In cases involving the Hatch - Waxman Act and issues involving the expiration of pharmaceutical patents and competition between branded drug companies and generic manufacturers, our antitrust litigation graphics can illuminate a complicated industry and a complex regulatory scheme as below:

(2) «life cycle management strategies» to maximize the value of pharmaceutical patents.

Not exact matches

Big biotech and pharma companies are absolutely dependent on being able to successfully innovate by partnering with and acquiring disruptive startups because of the nature of the patent cliff in pharmaceuticals.

Generic pharmaceutical company Teva brought the suit against Pfizer hoping to produce a generic version of Viagra before Pfizer's patent was due to expire in 2014.

Aside from the various scandals, patent protection for drugs that accounted for half of Bristol's pharmaceutical revenue was nearing an end or otherwise in jeopardy.

Jazz said in a filing that it did so in response to the overall takeover environment for pharma companies and in light of a patent litigation settlement that allows Hikma Pharmaceuticals to sell a generic version of Xyrem with Jazz receiving royalty payments on those sales.

Meanwhile, the patent term restoration provisions are likely to increase health care costs in Canada by delaying the availability of generic pharmaceuticals due to the extension in the term of protection for patented pharmaceuticals.

CETA establishes patent restoration and patent appeal rules that will extend the term of patent protection for pharmaceutical products, thereby increasing consumer prices and royalty outflows.

He represents pharmaceutical companies both large and small on a myriad of issues, as well as several universities in both patenting and licensing to outside investors.

While terms like «patent protection» and «public domain» were clearly part of the IPR debate, it also stretched to the cost of drugs and the availability of medicines, encompassing terms like «health advocates» and «pharmaceutical companies.»

Assuming that the patented compound even makes it to the market, the statement that they only have a few years of exclusivity is definitely true — the market exclusivity for pharmaceuticals is almost always less than half of the patent exclusivity.

The implications for digital and intellectual property issues are particularly important, with chapters on e-commerce and telecommunications services, an extension of patent protections for pharmaceutical drugs could raise health care costs by millions of dollars, and protections for hundreds of geographical indications may restrict Canadian producers of common cheeses, wines, and meats.

As big pharmaceutical companies find that the patents for some of their blockbuster drugs are expiring, they are desperately reaching out to replenish their drug pipelines.

It is hard to believe, for example, that Canada could not in the end find common ground with the US on some extension of patent protection for pharmaceuticals, since it was able to do so in the just - completed negotiations with the EU, or that an extension of the term of copyright protection from 50 to 70 years from the agreed baseline would have much if any real practical impact on Canada although it would be seen as a gain by the US given the heavy copyright portfolios of US entertainment companies, allowing them an additional period of time to exploit their copyrighted content.

An Indian generic drug company on Monday urged a federal appeals court to reconsider a recent decision that revived a patent infringement case against Google LLC, saying the ruling could spur «vexatious lawsuits» by makers of brand - name pharmaceutical products.

One of the few negatives on an otherwise fairly positive day of trading was the 5 % decline of Reckitt Benckiser, producers of a drug used to help get drug users off of Heroin called Suboxone, which acts as a replacement for the Class A. Reckitt's patent for Suboxone is due to expire in the relatively near future, so they have been trying to push doctors and other pharmaceutical vendors towards their film version of the drug, which is still under patent and will be for quite some time.

Analysts say that Trump might be interested in any number of proposals, like forcing Japan to import more US cars or agreements on patent laws that benefit US pharmaceutical companies.

The jury still must consider what damages to award to Merck and its co-owner of the patents, Ionis Pharmaceuticals Inc., for past sales, Kenilworth, N.J. - based Merck said in a statement.

No. 3: The year of big pharma In the past five years, big cap pharmaceutical stocks have lagged biotech stocks because they've struggled to fill revenue gaps created by the patent cliff.

For example, the pharmaceutical industry has actively stymied efforts to address problems of patent trolls that affect many other industries.

It's rare that it's tested in the USA because of the pharmaceutical industry's influence of dominating medicine with synthetic chemicals that can be patented.

The latter research findings form the basis for patents and clinical studies with the aim to create a pharmaceutical drug for relief of menopausal symptoms.

Five years later, Gilead became the first pharmaceutical company to sign an agreement with the newly formed Medicines Patent Pool — an organisation formed to coordinate the licensing of patent - protected medicines so that they can be produced in generic form for low income counPatent Pool — an organisation formed to coordinate the licensing of patent - protected medicines so that they can be produced in generic form for low income counpatent - protected medicines so that they can be produced in generic form for low income countries.

He has written extensively on pharmaceutical patents, parallel importation, antitrust law, commercialization and other uses of data, and the role of intellectual property policy in shaping these diverse areas.

In the last decade, Toronto companies held 61 % of U.S. patents granted to Canadian biotech firms, with the companies Aventis Pasteur, NPS Allelix Pharmaceuticals, Hemosol, Visible Genetics, and Spectral Diagnostics ranking in Canada's top five.

One of the most important drivers of change in the pharmaceutical industry was a wave of patent expirations that really picked up steam in 2010.

Then immunotherapy firm Juno Therapeutics shook hands with gene - editing start - up Editas to create anticancer immune cell therapies; Vertex Pharmaceuticals and Crispr Therapeutics, another start - up, inked an agreement that could be valued at $ 2.6 billion; while Regeneron Pharmaceuticals formed a patent licence agreement with ERS Genomics, which holds the rights to the foundational Crispr intellectual property from Emmanuelle Charpentier, one of the Crispr pioneers.

As the pharmaceutical industry's blockbuster drugs fall off the patent cliff, with precious few drugs in the pipeline to replace them, there are signs that big pharma could turn more of its attention to biologically derived medicines.

The Plant Patent Act of 1930 pushed food science forward and helped power agribusiness into the second most gainful enterprise in the nation (after pharmaceuticals).

Marnett, whose university has patented this class of permanent COX - 2 inhibitors, hopes to team up with a pharmaceutical company to come up with an even more effective version of this new superaspirin.

As well, pharmaceutical companies are looking for new ways to address their two - pronged pipeline problem: many big - name blockbuster drugs will soon lose their patents and, perhaps more important, there is a dearth of new blockbusters headed to the market.

Of the three leaders in U.S. Patent and Trademark Office patents, U.S. and EU inventions are concentrated in chemistry and health, including pharmaceuticals and biotechnology.

Considerations about patenting and intellectual property exist in industry, although the same is true for academia these days, says Alan Goldhammer, vice president of scientific and regulatory affairs for Pharmaceutical Research and Manufacturers of America (PhRMA), an organization that represents the country's leading pharmaceutical research and biotech companies.

According to Lisa Conte, founder of Shaman Pharmaceuticals, which supported the treaty even in Rio, the new interpretation «gave those companies the confidence that if they are working in these countries they will have patent protection».

It lets pharmaceuticals companies claim extension of the life of a patent on a new drug, to compensate for the years lost in testing it for safety before sale.

* Eliminate «pay - for - delay» strategies in which a pharmaceutical company with a brand name drug shares profits on that drug with a generic drug manufacturer for the remainder of a patent period, effectively eliminating a patent challenge and competition.

The test called SkimuneTM, which is trademarked and has a patent pending, has been successfully tested by a number of large pharmaceutical companies on drugs in development and provides a reliable result within two weeks.

«That level of proof is never going to be forthcoming in the current environment because it requires doing a really extensive clinical trial series, and given that a pharmaceutical company can't patent whole plant marijuana, it's in no company's interest to do that.»

On 2 April, a draft report on pharmaceutical patents that calls for limiting the reach of intellectual property (IP) was unveiled.

These promising results have already raised the interest of the pharmaceutical industry and led the researchers to patent DGKi as a drug target, as they are keen to explore the issue further, searching for molecules that strongly inhibit DGKi without causing side - effects.

«Patents are essential to development of pharmaceuticals, diagnostics and processes,» he says, reflecting the general opinion of the biotech industry.

Fourteen members of the council's Parliamentary Assembly have released a document charging that «pharmaceutical companies have influenced scientists and official agencies... to alarm governments» in order to «promote their patented drugs and vaccines».

Choosing London to host the court specializing in life sciences patents plays to Britain's strength in pharmaceutical research, says Richard Jennings, deputy director of Cambridge Enterprise, a company that helps commercialize inventions at the University of Cambridge in the United Kingdom (U.K.).

Varying strengths of risperidone tablets, manufactured by TEVA Pharmaceuticals USA, have been approved, although the labeling of the generic risperidone might differ from that of Risperdal because some uses of the drug are protected by patents and exclusivity, the agency said.